Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. A Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE2
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Safety and Efficacy Study of Radioembolization in Combination With Durvalumab in Locally Advanced and Unresectable HCC
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Diadem to Investigate the Activity and Safety of Durvalumab
- Status
- COMPLETED
- Phase
- PHASE2
Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Immunotherapy in Patient With Poor General Condition
- Status
- COMPLETED
- Phase
- PHASE2
Microbiome Immunotherapy Toxicity and Response Evaluation
- Status
- UNKNOWN
- Phase
- N/A
DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab Long-Term Safety and Efficacy Study
- Status
- COMPLETED
- Phase
- PHASE4